Clayton Rabideau

Clayton is the founder of Syntensor, a startup that develops frontier models for drug development and human genetics with a particular focus on predicting the underlying drivers of clinical trial outcomes and trait prediction from human genomes.

‍

Syntensor Incorporated
Wednesday
May 07
AI-Driven Breakthroughs: Accelerating Drug Discovery and Genetic Medicine
8:55 AM

-

9:25 AM

In an era where AI is transforming medicine, drug discovery and genetic therapies are entering a new frontier. This session will explore how AI accelerates the development of innovative therapies, from optimizing molecular designs to enabling precise, tissue-specific genetic interventions. Discover how cutting-edge AI technologies are advancing therapeutic modalities, enhancing delivery systems, and unlocking the potential of personalized medicine. Join leading experts as they share groundbreaking insights into AI-driven innovation and its profound impact on the future of drug discovery and genetic medicine.

Conference Pass

2,495

USD

Keynotes & Firesides

Workshops & Breakouts

1:1 Partnering App

Meals & Receptions

Session Recordings

Until Friday April 18th

Full Rate:

$3,495

Other Speakers

Copyright SynBioBeta 2025